LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial.

Authors :: Vano, Y.
Elaidi, R.T.
Bennamoun, M.
Chevreau, C.M.
Borchiellini, D.
Pannier, D.
Maillet, D.
Gross-Goupil, M.
Tournigand, C.
Laguerre, B.
Barthélémy, P.
Joly, F.
Gravis, G.
Caruso, S.
Sun, C-M.
Verkarre, V.
Fridman, W-H.
Zucman-Rossi, J.
Sautès-Fridman, C.
Oudard, S.
Source :: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS1157-S1157. 1p.
Publication Year :: 2020

Subjects :: *PROTEIN-tyrosine kinase inhibitors
*NIVOLUMAB
*RENAL cancer
*BIOMARKERS
*METASTASIS

Full Text Access

Tools